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ABSTRACT 
Chronic pain is one of the most debilitating and repeatedly reported symptoms by rheumatoid 
arthritis (RA) patients. Despite good disease control achieved with disease modifying anti-
rheumatic drugs (DMARDs), joint pain remains a major problem for a subgroup of patients. 
Therefore, it appears episodes of joint inflammation can have long-term effects on the 
peripheral sensory nervous system. Additionally, changes in the central nervous system may 
contribute to chronification of RA pain. High mobility group box-1 protein (HMGB1) is an 
important molecule in the pathogenesis of RA, but the role of HMGB1 in RA associated pain 
has not been studied. Thus, the involvement of spinal and peripheral HMGB1 in rheumatoid 
arthritis-induced pain is the focus of this thesis.  
In Paper I, we characterized the collagen antibody-induced arthritis (CAIA) model from a 
pain perspective. As expected, injection of collagen type II antibodies induces transient joint 
inflammation and pain-like behavior. Surprisingly, pain-like behavior did not normalize when 
the inflammation resolved. We found that transient antibody-induced joint inflammation led 
to long-lasting mechanical hypersensitivity that outlasted the inflammation. Buprenorphine 
and gabapentin attenuated pain like behavior in both the inflammatory and late “post-
inflammatory” phase of the model, whereas diclofenac was antinociceptive only during the 
inflammatory phase. This indicates that there is a temporal shift in the mechanisms that 
maintain arthritis-induced nociception. The CAIA model can thus be used to explore 
mechanisms of persistent pain induced by inflammation in the articular joint. 
In Paper II and III, we investigated the spinal role of HMGB1 in arthritis-induced pain and 
sex-dependent microglial involvement in disulfide HMGB1 mediated nociception. Peripheral 
joint inflammation in the CAIA model increases expression and extranuclear levels of 
HMGB1 in the lumbar spinal cord. Blocking the endogenous action of HMGB1 with 
HMGB1 inhibitors attenuated CAIA-induced mechanical hypersensitivity in both male and 
female mice. A pronociceptive effect dependent on the redox state of HMGB1 was also 
revealed. The disulfide, but not the all-thiol or oxidized form, of HMGB1 induced 
nociception in male and female mice after intrathecal delivery. This effect was regulated via 
toll-like receptor 4 (TLR4) and associated with cytokine and chemokine production and 
elevated expression of factors related to increased glial cell reactivity. Intrathecal delivery of 
minocycline attenuated the disulfide HMGB1 induced hypersensitivity in male but not in 
female mice. Global protein analysis of lumbar spinal cords from male and female mice 
injected intrathecally with HMGB1 and vehicle or minocycline showed that 36 proteins were 
differentially expressed between male and female injected with HMGB1 and that 44 proteins 
in males and 8 in females were altered in mice receiving HMGB1 and minocycline. 
Interestingly, up-regulation of antinociceptive and anti-inflammatory molecules was found in 
male but not in female mice after intrathecal injection of HMGB1 and minocycline. This 
work points to a prominent and redox-dependent role of HMGB1 in spinal pain signal 
transmission. 
In Paper IV, we demonstrated that a repetitive systemic injection of a HMGB1 neutralizing 
antibody attenuates CAIA-induced nociception in male but not in female mice. Intraarticular 
injection of disulfide but not all-thiol HMGB1 induced mechanical hypersensitivity in both 
male and female mice, but with a more pronounced induction of cytokine and chemokine 
mRNA expression in male compared to female mice. Moreover, nociception induced by 
disulfide HMGB1 is mediated by TLR4 expressed on nociceptors and myeloid cells in male 
and female mice, with a stronger contribution of TLR4 on myeloid cells in male mice. 
In summary, we have described novel redox state and sex-dependent roles of HMGB1 in 
nociception at spinal and peripheral sites in a model of arthritis-induced pain. These results 
also reveal sex-dependent analgesic pharmacology and highlight the importance of taking sex 
into account in preclinical pain research. While further studies are warranted in order to 
further advance our knowledge on the role of HMGB1 in pain pathology, the work in this 
thesis highlights HMGB1 as an intriguing new target for pain relief. 
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INTRODUCTION 
1.1 PAIN 
International Association for the Study of Pain (IASP) states, ‘Pain is an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage, or described in 
terms of such damage’ (https://www.iasp-pain.org/Taxonomy). Chronic pain is one of the 
most under-recognized, under-treated medical problems of the twentieth century. Globally, 
approximately 10-20 % of the population suffers from pain, resulting in reduced quality of 
life for the individual (Apkarian et al., 2009; Macfarlane, 2016; van Hecke et al., 2013). 
Failure to recognize that chronic pain is a serious health problem, which results in 
substandard pain management, is a part of the problem. Also, drug development in the area of 
chronic pain has hitherto been insufficient, and there are currently few available effective 
treatments for chronic pain conditions. Without adequate pain relief, individuals with 
persistent pain often endure physical and psychosocial problems, such as an inability to work 
and perform daily chores, decreased activity and muscle wasting, fatigue, sleep disturbances, 
social isolation, anxiety and depression (Breivik et al., 2006; Hunt & Mantyh, 2001). As a 
consequence, chronic pain is not only devastating for the individual but also generates a huge 
socio-economical burden in the form of medical costs, sick leave, and loss of productivity 
(Breivik et al., 2006). 
In a survey from 15 European countries 40% of the chronic pain patients reported having 
joint pain, mainly due to osteoarthritis and rheumatoid arthritis (M. L. Andersson et al., 2013; 
Lluch et al., 2014). Hence, it is critical to increase our understanding of how arthritis-induced 
chronic pain is regulated in order to identify new targets for pain relief. 
1.2 PAIN BIOLOGY 
Pain is a sensory experience that is basically unpleasant and associated with hurt and 
discomfort. It may vary with regard to intensity, quality, duration and referral. Pain can be 
adaptive or maladaptive. Adaptive pain provides a defense mechanism to protect the 
organism from injury and promotes healing in injured tissue (Julius & Basbaum, 2001; 
Woolf, 2004). In contrast, maladaptive pain is the type of pain that persists long after 
resolution of tissue damage and leads to problems rather than protecting the organism 
(Woolf, 2004). Painful stimuli are detected by the nociceptors (see below) and the 
information conveyed by relaying sensory neurons to different centers in the brain, ultimately 
giving us the sensation of pain. Furthermore, pain is differentially categorized based on how 
it is triggered, such as nociceptive (by chemical irritant, heat, cold, intense mechanical force), 
neuropathic (peripheral nerve injury) and inflammatory (tissue damage and activation of 
macrophages, mast cells, neutrophils and granulocytes) (Hunt & Mantyh, 2001; Julius & 
Basbaum, 2001; Woolf & Salter, 2000). 
 2 
1.2.1 Nociceptors and transmission of pain 
Nociceptors are the peripheral sensory nerves that detect painful noxious stimuli. Nociceptors 
are categorized based on their diameter, degree of myelination and conduction velocity; C 
fibers, smaller in diameter (0.2-1.5 µM) have a low conduction speed (0.5-2 m/s) and are 
activated by painful stimuli, Aδ-fibers are medium sized in diameter (1-5 µM) with thin 
myelination, a somewhat higher conduction speed (5-35 m/s) compared to C fibers, that 
mainly carry information related to the pain and temperature, Aβ fibers are large diameter (6-
12 µM) with high myelination and high conduction speed (35-75 m/s) that carry information 
related to touch, and Aα fibers are large diameter fibers (13-20 µM) with high myelination 
and faster conduction speed (80-120 m/s) that carry information related to the proprioception. 
Nociceptors are also categorized based on the expression of peptides and ion channels. C-
fibers that express substance-P and calcitonin gene-related peptide (CGRP) are referred to as 
peptidergic nociceptors (Basbaum et al., 2009). These neurons also express tyrosine kinase 
receptor (TrkA) for nerve growth factor and express transient receptor potential vanilloid 1 
(TRPV1, also known as capsaicin receptor) that is activated by heat stimuli. Nociceptors that 
stain positive with Isolectin B4 and expressed P2X3 receptor for ATP, and typically do not 
release peptides such as substance-P and CGRP upon stimulation are referred to as non-
peptidergic nociceptors (Basbaum et al., 2009; Zylka, 2005).  
              
Figure 1. Schematic illustration for transmission of pain signal from periphery to the brain. Peripheral nociceptors (primary 
afferent neuron) detect the noxious stimuli and send signal to the spinal cord, where the signal transfer to the second order 
(projection neuron) which send signal to the brain (Reprinted with permission, Adapted from Talbot et al., 2016). 
The cell bodies of nociceptors reside in dorsal root ganglia (DRG) with an exception for the 
sensory nerves innervating the face, which are located in the trigeminal ganglia (TG). 
Nociceptors are pseudo-unipolar in morphology with the cell body located in the DRG from 
which two axonal branches depart, one towards the peripheral tissue that it innervates and one 
towards the dorsal horn of the spinal cord where it makes synaptic contact with the second 
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order neuron (Basbaum et al., 2009). When nociceptors detect peripheral noxious stimuli, the 
peripheral nerve terminal is activated, and the stimulus is converted into electrical current 
(transduction) in the form of action potentials. The action potentials are conducted from the 
periphery to the central terminal. Nociceptors make synaptic contact with projection neurons 
and interneurons in the spinal cord, and the signal in the primary afferent nociceptor is 
transmitted to the second order neurons across the synapse (Basbaum et al., 2009; Woolf, 
2004). The signal is conveyed to different centers of the brain giving us the perception of pain 
(Figure 1).  
1.2.2 Innervation of nociceptors in joint 
Different joint structures such as ligaments, fibrous capsules, periosteum, synovial layer, 
meniscus and surrounding bone structures are innervated by sensory nociceptive fibers. 
While Aβ fibers are mostly present in the ligament and fibrous capsule, Aδ and C fibers 
innervate in the ligament, fibrous capsule, meniscus, synovial layer, trabecular bone, 
periosteum and bone marrow (Mantyh, 2014). Some populations of nociceptive fibers in the 
joint structure are silent and become activated during the injury, damage or inflammation. 
Upon activation, the silent fibers can either be spontaneously active or display reduced 
threshold to the stimulus (Mantyh, 2014; Schaible et al., 2009). The noxious sensation from 
the joint structure can be evoked by different mechanical and chemical stimuli (Schaible et 
al., 2009).  
       
Figure 2. Schematic illustration of the termination of different sensory neuron populations in the dorsal horn of the spinal 
cord from joint and bone structure, and in the skin. Bone/joint structure innervated with TrkA + fiber, approximately 60% Aδ 
fiber and 20% of C fibers, and in the skin it is 10% Aδ-fiber and 20% C-fiber (Reprinted with permission, Adapted from 
Mantyh P. et al. 2014). 
As compared to the skin, the majority of the sensory neurons innervating the bone and joint 
structure are thinly myelinated TrkA+ and/or peptidergic fibers with minor innervation by Aβ 
and TrkA- peptide poor fibers (Figure 2) (Jimenez-Andrade et al., 2010; Zylka, 2005). Nerve 
fibers in the bone marrow and cortical bone are most often co-localizing with blood vessels, 
while the periosteum is densely innervated in a grid pattern (Martin et al., 2007). Intriguingly, 
the articular cartilage of the joint lack innervation of sensory nerve fibers, so nociception 
resulting from damage to the cartilage itself has likely originated in an adjacent structure, like 
subchondral bone and synovium (Mantyh, 2014). This literature provides the importance of 
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knowing the microenvironment of the joint structure, and subpopulations of nociceptors in 
the joint and skin. 
1.2.3 Cytokines/chemokines as neuronal activators (peripheral sensitization) 
Cytokines and chemokines are classical regulators of immune responses as well as major 
players in neuroinflammation. Cytokines are a diverse group of small proteins; chemokines 
represent one family of cytokines. They are involved in the interaction between immune and 
non-immune cells (Vilček, 2003). Under physiological and pathological conditions, cytokines 
and chemokines are released in response to stimuli from cells of both the immune and 
nervous systems. In the incidence of tissue injury, immune cells are attracted to the injury site 
(Figure 3) and secrete mediators, including cytokines and chemokines that can directly or 
indirectly sensitize the peripheral endings of primary afferents giving rise to peripheral 
sensitization, reviewed in (Taylor et al., 2011). Recent evidence shows that receptors for 
different cytokines/chemokines are expressed by nociceptors and glial cells (Miller et al., 
2009). It has been reported that cytokines and chemokines activate nociceptors in different 
experimental models as well as in human (Alboni & Maggi, 2015; Khairova et al., 2009; 
Miller et al., 2009; K. Ren & Dubner, 2010; Schaible et al., 2010). Intraarticular injection of 
TNF, IL1-β IL6 and IL17 generates nociception in the normal knee joint in rodents (Schaible, 
2014). Additionally, TNF, IL1-β and IL-6 have been shown to increase the synaptic plasticity 
in the dorsal horn of spinal cord (Lamina II) (Kawasaki et al., 2008; K. Ren & Dubner, 2010). 
A specific chemokine, CCL2, is expressed by peripheral neurons and released during the 
nerve injury (L. Zhang et al., 2017). In this thesis, cytokines (TNF, IL1-β, IL6), and 
chemokines (CCL2, CXCL1, CXCL2) are used as the readout for the tissue insult. 
 
Figure 3. Schematic illustration of the molecules involved in the peripheral sensitization. Inflammatory mediators and other 
factors bind to their receptor present on the nerve terminal of the nociceptors to generate neuronal excitability in peripheral 
nociceptors. (Reprinted with permission, Adapted from Ji RR et al., 2014) 
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1.2.4 Spinal neuron-glial signaling in neuronal plasticity (central 
sensitization) 
Historically the main function of glial cell (astrocytes and microglia) in central nervous 
system was thought to be providing structural and nutritional support for the neuronal 
network. However, emerging evidence suggests that central astrocytes and microglia perform 
a much wider range of functions. Rapidly increasing number of reports indicate that spinal 
glial cells plays an important roles in the maintenance of inflammatory and neuropathic pain 
in collaboration with neurons (Gosselin et al., 2010; McMahon & Malcangio, 2009; Milligan 
& Watkins, 2009; Tsuda, 2016). Peripheral injury and insult prolong and amplify nociceptive 
signal conduction, which promotes the release of neurotransmitters (glutamate, ATP), 
cytokines (CCL2) (L. Zhang et al., 2017) and neuropeptides (substance P, CGRP, BDNF) 
from the primary afferent neuron into the central synapse. Resident spinal glial cells express 
broad categories of receptors including purinergic, toll-like, cytokine, and neurotransmitter 
receptors (McMahon & Malcangio, 2009; Wolf et al., 2017). Thus factors released from 
nociceptors can activate receptors on glial cells, which activate intracellular signaling 
pathways like the p38/MAPK pathway in microglia and JNK/MAPK pathway in astrocytes. 
In turn, glia release factors that potentiate the activation of release of neurotransmitter from 
the presynaptic afferent and increase excitability of the second order (projection) neuron 
(McMahon & Malcangio, 2009). It has been shown previously that, proinflammatory 
cytokines such as TNF, IL1-β and IL6 regulate synaptic plasticity in the spinal cord (Alboni 
& Maggi, 2015; Kawasaki et al., 2008; Khairova et al., 2009). Studies have shown that spinal 
delivery of “glia inhibitors” or agents targeting glia-specific receptors or signaling pathways 
prevent or reverse pain-like behavior in a 
number of experimental models of pain, 
further supporting active role of glia cell in 
spinal pain signal transmission (Gosselin et 
al., 2010; McMahon & Malcangio, 2009; 
Milligan & Watkins, 2009; Tsuda, 2016). 
Beside is a cartoon illustrates the interaction 
between astrocytes, microglia and neurons 
(Figure 4). 
 
Figure 4. Schematic diagram represents the possible 
interaction between spinal neuron-.microglia and 
astrocytes, for maintenance of central sensitization 
(Reprinted with permission, Adapted from Kettenmann et 
al. 2012, Neuron) 
 
1.2.5 TLRs in chronic pain 
Toll-like receptors (TLRs) are 
transmembrane-signaling receptors that 
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play a critical role in innate and adaptive immune responses by recognizing factors of 
invading microbes. So far, more than 10 different TLRs with distinct ligand specificities have 
been identified. In the central nervous system, microglia and astrocytes express various 
TLRs, including TLR2 and TLR4. In particular, TLR4 has been associated with altered pain 
processing. TLR4 is activated by LPS (Miyake, 2004; Raetz et al., 2006) and intrathecal 
injection of LPS induces tactile allodynia (Christianson et al., 2011; Saito et al., 2010). 
Nociception observed following nerve injury and joint inflammation is attenuated in mice 
lacking functional TLR4 (Christianson et al., 2011; Tanga et al., 2005), in rats following 
spinal TLR4 knock-down (Tanga et al., 2005) and in mice receiving TLR4 antagonists 
(Bettoni et al., 2008; Christianson et al., 2011; Hutchinson et al., 2009). Importantly, 
preventing TLR4-mediated signaling suppresses spinal microglial activation and decreases 
nerve injury-induced spinal release of pro-inflammatory cytokines (Tanga et al., 2005). As 
TLR4 deficiency and TLR4 antagonists attenuate hypersensitivity in the absence of 
exogenous TLR4 ligands, TLR4 appears to be activated by endogenous ligands and play an 
important role in spinal nociceptive processing. Noteworthy, in earlier work, we found an 
increase in mRNA for the endogenous TLR4 ligand HMGB1 in spinal cords from mice 
subjected to experimental arthritis (Christianson et al., 2010). HMGB1 was originally 
considered to only have nuclear actions, but is now known to function also extra-cellularly as 
a pro-inflammatory molecule (U. Andersson & Tracey, 2011). 
1.3 HIGH MOBILITY GROUP BOX 1 (HMGB1) 
High mobility group (HMG) proteins are nuclear proteins, which were first extracted from 
calf thymus in 1973 (Goodwin & Johns, 1973; Kang et al., 2014). These proteins were 
characterized by their high solubility in 10% trichoric acid and fast migration on 
polyacrylamide gel electrophoresis without aggregation, hence explaining the attribution of 
the name (Goodwin & Johns, 1973). In 2001, the nomenclature committee organized in the 
National Cancer Institute USA categorized HMG into three different super families: HMGB 
(previously known as HMG-1/2), HMGA (previously known as HMG-14/17) and HMGN 
(previously known as HMG-I/Y) (Bustin, 2001). 
High mobility group box 1 (HMGB1) protein, previously known as HMG-1, amphoterin or 
p30, is a 28 kDa non-histone protein that binds to nuclear DNA and therefore plays an 
important physiological role in DNA replication, transcription, recombination, repair and in 
genomic stability. It has been highly conserved in evolution and is ubiquitously expressed in 
most cell types. HMGB1 shuttles between nucleus and cytoplasm but in physiological 
conditions, it is found primarily in nucleus where it binds to chromatin structure (Isackson et 
al., 1980). More recently, extracellular HMGB1 was described as a danger signal mediating 
the activation of the immune system by binding to TLRs and receptor for advance glycation 
end product (RAGE). Thus, it plays a crucial pathological role in inflammation, cell growth, 
cell proliferation and cell death. The great potential of HMGB1 as danger/stress signal both in 
inflammatory, potentially painful conditions, motivated the studies developed during this 
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thesis. Thus, its more relevant properties and functions will be further explored in the 
following sections. 
1.3.1 Structure and cellular localization 
HMGB1 is a 215 amino acid protein consisting of two different HMG boxes and an acidic 
tail. HMG Box A resides from 9-79 amino acid (aa), HMG box B from 95-163 aa and the 
acidic tail from 186-215 aa (Bianchi et al., 1992). Box A and B are DNA binding domains 
which play a role in bending double-stranded DNA in helix strands to form DNA chaperone. 
Nuclear immigration signal (NES) is present in the DNA binding domain, which is mediated 
via nuclear exportin chromosome region maintenance 1 (CRM1). However, the steady state 
of HMGB1 in the nucleus is maintained by two NLS domains; nuclear localization domain 1 
(NLS1), which resides from 28-44 aa, and nuclear localization domain 2 (NLS2), which 
resides from 179-185 aa (Bonaldi et al., 2003; Kang et al., 2014).  
In physiological states, HMGB1 accumulates in the nucleus and binds to DNA acting as a 
chaperone and regulates various functions such as nucleosome stability and sliding, 
nucleosome release, genome chromatization, V(D)J recombination, as well as DNA 
replication and repair. Furthermore, it also acts as a transcriptional factor regulating the 
expression of certain genes (Kang et al., 2014). In general, the nuclear/cytoplasmic 
distribution ratio of HMGB1 is about 30:1 in many rat tissues (Kuehl et al., 1984). 
During stress, injury and inflammation, the amino acid lysine in Box A and B undergoes 
acetylation and HMGB1 loses its binding affinity towards DNA. This results in its 
active/passive release into an extracellular milieu where it has different functions (H. Yang et 
al., 2013). HMGB1 interacts with RAGE through the amino acid sequence 150-183, which 
subsequently promotes cell migration and metastasis (Huttunen et al., 2002). The amino acid 
sequence 89-108 is responsible for TLR4 receptor binding that leads to cytokine production, 
whereas the amino acid sequence 7-74 is mainly responsible for the p53 transactivation 
binding domain for gene transcription. Extracellular Box A has been reported as the 
antagonist for HMGB1, and its antagonist activity is more potent when it is fused to the C-
terminal acidic tail (Gong et al., 2010). Moreover, Box B acts as a pro-inflammatory mediator 
(J. Li et al., 2003) and C-terminal acidic tail displays antibacterial activity (Gong et al., 2009) 
(Figure 5). 
       
Figure 5. Detailed HMGB1 structure, with different receptor/functional binding domains and three cysteines (Open access, 
Adapted from Wan et al. 2016). 
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A previous report has shown that cytoplasmic HMGB1 acts as a positive regulator of 
autophagy. During autophagic stimuli, HMGB1 translocates into the cytosol and cytoplasm, 
binds to beclin-1 and induces autophagy (D. Tang et al., 2010). Furthermore, the presence of 
HMGB1 in the cell membrane relates to its role in neurite growth, activation of platelets, cell 
differentiation, innate immunity as well as in cell adhesion and invasion (more details in 
Kang et al. 2012). In 1991, Merenmies et al. showed that HMGB1 distributed throughout 
filopodia (cytoplasmic projections) of neuroblastoma cells enhances neurite growth 
(Merenmies et al., 1991). HMGB1 also activates platelets to induce formation of neutrophil 
extracellular traps (NET) (Mitroulis et al., 2011). Lastly, extracellular HMGB1 plays an 
important role in different pathological conditions upon specific binding to its receptors. 
Actively and passively released HMGB1 triggers the innate and adaptive immune systems. 
For instance, binding of HMGB1 to TLRs activates immune cells such as macrophages, T 
cells, B cells and NK cells (G. Li et al., 2013).  
1.3.2 Translocation and release 
HMGB1 lacks the leader signal sequence to be released through the classical pathway; hence 
HMGB1 cannot be secreted via the classical endoplasmic reticulum secretory pathway. 
Several mechanisms have been reported concerning the translocation of HMGB1 from the 
nucleus to the cytoplasm and its subsequent extracellular release. These mechanisms include 
transcriptional modifications, CRM1-mediated nuclear export, reactive oxygen species 
(ROS), and calcium and nitric oxide (NO) signaling. These mechanistic cascades are also 
mediated by TNF-α, nuclear factor (NF)-kβ, Notch, mitogen-activated protein kinase 
(MAPK), signal transducer and activator of transcription (STAT), inflammasome, p53, PPAR 
and lysosomes in a dependent manner (Kang et al., 2014). 
HMGB1 is actively released from the nucleus in response to exogenous microbial stimulus 
such as LPS (Wang et al., 1999), lysophosphatidylcholine (LPC) (Gardella et al., 2002), 
mycobacterial infection (Grover et al., 2008), CpG-DNA (Ivanov et al., 2007), as well as 
endogenous stimuli such as IFN-α (Jiang & Pisetsky, 2006), IFN-β (Lu et al., 2014), TNF 
(Wang et al., 1999), NO (Tamura et al., 2011), hydrogen peroxide (D. Tang et al., 2007), 
peroxynitrite hyperlipidemia (Haraba et al., 2011), kynurenic acid (KYN) (Tiszlavicz et al., 
2011), ATP (Eun et al., 2014) neuropeptide Y (NY) (J. R. Zhou et al., 2013) and other stimuli 
(ethanol) (Whitman et al., 2013). Other than active secretion, HMGB1 can also be released 
passively after cellular death such as apoptosis, necrosis, autophagic or lysosomal cell death 
and tissue injury. The mechanisms underlying this passive release are dependent on several 
mediators such as PARP1, RIP3, cathepsin, anti-oxidant enzyme, DNase , caspase and ATG 
pathway  
1.3.3 Redox state, receptors and signaling cascade  
HMGB1 is passively and actively released from the nucleus into the extracellular milieu. It is 
predominantly present in the fully reduced form in the nucleus, and it can be oxidized in the 
cytoplasmic compartment after ROS production (Daolin Tang et al., 2011). Recently, it has 
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been shown that three cysteine amino acids (C), at positions 23, 45 and 106, play an 
important role in the HMGB1 redox state, receptor binding profile and the activation of the 
corresponding signaling pathway, which defines the physiological/pathological action of 
HMGB1 (H. Yang et al., 2012). When all three cysteines are reduced by an (SH) group, the 
protein is called All thiol (at) HMGB1 (all-thiol HMGB1 or HMGB1C23hC45hC106h). The 
all-thiol HMGB1 binds to RAGE) and acts as a chemo-attractant. It also forms a complex 
with the CXCL12 chemokine and potentiates chemotaxis by binding to the CXCR4 receptor. 
HMGB1 with a disulfide bond between C23 and C45, together with a thiol group at C106, is 
called disulfide (ds) HMGB1 (disulfide HMGB1 or HMGB1C23-C45C106h) (H. Yang et al., 
2012). This form binds to TLR4 and displays cytokine-inducing properties via activation of 
intracellular MAP kinase signaling. When all cysteine positions have a sulphonyl group 
(SO3H), HMGB1 is in its fully oxidized form (oxHMGB1 or HMGB1C23soC45soC106so), 
but the physiological function of this redox state of HMGB1 is still not clear. These redox 
forms of HMGB1 can be identified in different body fluids of patients with different 
pathological conditions (Antoine et al., 2014) (Figure 6). 
     
Figure 6. Three cysteines and their important roles in the redox regulation of HMGB1 (Reprinted with 
permission, Adapted from Jungo et al. 2015) 
Besides the receptors mentioned above, HMGB1 may bind to partner molecules potentiating 
their effects. For instance, HMGB1 binds to IL-1β and LPS to potentiate their cytokine-
inducing capacity via IL-1R and TLR4, respectively (Wahamaa et al., 2011). In addition, 
HMGB1-nucleosome complex have action through TLR2 receptors (Pisetsky, 2014) (Figure 
7). 
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Figure 7. Different redox forms of HMGB1 and their action on different receptors (Reprinted with permission, 
Adapted from Kato et al.; 2015) 
1.4 RHEUMATOID ARTHRITIS AND PAIN 
Approximately 0.5-1% of the world’s population suffers from rheumatoid arthritis (RA) 
(Cross et al., 2014). It is a chronic, systemic autoimmune disease characterized by synovial 
inflammation, cartilage destruction and bone erosion (Smolen & Aletaha, 2015). Prior to 
active disease, several antibodies can be detected in the systemic circulation such as 
rheumatoid factor (IgG and IgM), collagen type II and anti-citrullinated proteins (ACPA) 
(Nielen et al., 2004; Rantapaa-Dahlqvist et al., 2003). If circulating antibodies persist (thus 
becoming pathogenic), immune cells are recruited leading to the active state of RA disease. 
Chronic pain is one of the most distressing symptoms in RA patients (Altawil et al., 2016). 
Recent studies have shown that pain symptoms start before the manifestation of RA disease. 
During the active phase, inflammatory mediators at the site of inflammation trigger the 
sensory neurons (Bas et al., 2016). These stimuli can become painful with persistent 
activation of peripheral neurons. Despite effective therapeutic results with disease modifying 
anti-rheumatic drugs (DMARDs), such as TNF neutralizing and IL-6 receptor binding 
antibodies, patients still report pain as their most disturbing problem (Altawil et al., 2016; 
Firestein, 2003; McInnes & Schett, 2007). Pain in RA has been associated mainly with tissue 
injury, and inflammatory processes in the small and big joints, but accumulating clinical and 
experimental data indicate that in addition to peripheral mechanisms, neurochemical and 
structural changes within the sensory system may affect central pain processing as well (Bas 
et al., 2016; Neumark et al., 1979). Even though the new DMARDs have improved the 
prognosis, RA-associated joint pain remains a big problem and the mechanisms that maintain 
pain in RA remain unclear. Thus it is crucial to identify new players in these processes. 
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1.4.1 HMGB1 and rheumatoid arthritis 
Most of the evidence in the literature points towards the role of extra-nuclear HMGB1 in the 
pathogenesis of RA not only in human but also in experimental models. Levels of extra-
nuclear HMGB1 are elevated in the serum, synovial tissue and synovial fluid of arthritis 
patients (Hamada et al., 2008; Kokkola et al., 2002; Taniguchi et al., 2003). The increased 
levels of HMGB1 in synovial fluid are much higher in RA than osteoarthritis (Taniguchi et 
al., 2003). Macrophages from the synovial fluid induce the release of cytokines (TNF, IL-1β 
and IL-6) after stimulation with HMGB1 since these cells have high expression of TLR2, 
TLR4 and RAGE receptor (Huang et al., 2007; Taniguchi et al., 2003).  
In an experimental model of arthritis, HMGB1 expression is significantly elevated in the 
extracellular space and cytoplasm of fibroblasts, macrophages, synoviocytes and vascular 
endothelial cells (Palmblad et al., 2007). The presence of extranuclear HMGB1, TNF, IL-1β 
and VEGF (vascular endothelial growth factor) in proliferating synovial tissue may lead to 
the destruction of cartilage and bone (U. Andersson & Harris, 2010; Biscetti et al., 2016; 
Palmblad et al., 2007). Hypoxia is one of the prominent conditions in which HMGB1 leads to 
synovitis in the CIA (collagen-induced arthritis) experimental model. Immunohistological 
observations show that pimonidazole (hypoxic marker) co-localizes with HMGB1 in CIA 
model (Hamada et al., 2008). Elevated extranuclear HMGB1 enhances the function of tissue 
plasminogen activator and metalloproteinases, which leads to the destruction of cartilage and 
bone structure (Parkkinen & Rauvala, 1991). In addition to this, HMGB1 is also shown to 
play an important role in osteoclastogenesis by producing TNF via RAGE (Yamoah et al., 
2008; J. Yang et al., 2008; Z. Zhou et al., 2008). 
Injection of recombinant HMGB1 into murine knee joint leads to an inflammatory response 
with recruitment of immune cells and synovitis lasting for approximately 4 weeks, though the 
severity of the articular inflammation varies between mouse strains (Pullerits et al., 2003). It 
has been suggested that the inflammatory response of HMGB1 depends on IL-1 receptor 
activity since IL1-R knockout (KO) mice do not exhibit any signs of arthritis after HMGB1 
injection in the knee (Pullerits et al., 2003). Others have shown that HMGB1 
potentiates/synergizes the action of IL1-β by binding to its own receptor (IL-1R) (Wahamaa 
et al., 2011) with transactivation of the IL1-β promoter sites NF-IL6 (nuclear factor IL6) and 
PU.1 (myeloid and B cell-specific transcription factor) resulting in synergistic trans-
activation of IL1-β (Mouri et al., 2008). Taken together these findings strengthen the 
importance of HMGB1 in the pathogenesis of rheumatoid arthritis. 
1.4.2 HMGB1 and pain 
Mounting data from the past decade indicate that HMGB1 has an important pathological role 
in different pain conditions. The first report showing this association was in 2010 by Chacur 
and colleagues. They demonstrated that application of HMGB1 on the sciatic nerve, using 
pre-implanted indwelling peri-sciatic catheters, induced mechanical hypersensitivity in rats in 
a dose-dependent manner (Chacur et al., 2001). Similar findings were reported after 
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application of HMGB1 from autologous pulposus to the sciatic nerve in rat (Shibasaki et al., 
2010). Injection of HMGB1 to peripheral sites like intravesical, skin and joint, induce pain-
like behavior. In the periphery, the redox state of HMGB1 has been proven to be important in 
the induction of hypersensitivity as intraplantar and intra-articular injections of disulfide 
HMGB1, but not all-thiol HMGB1, induce mechanical hypersensitivity in naïve mice 
(Agalave & Svensson, 2015; Tanaka et al., 2013; Yamasoba et al., 2016), which was reversed 
by rh-thrombudilin (Tanaka et al., 2013) and the selective TLR4 antagonist LPS-RS 
(Yamasoba et al., 2016). Furthermore, intravesical instillation of disulfide HMGB1 but not 
all-thiol HMGB1 elicited dose-dependent abdominal mechanical hypersensitivity (bladder 
pain), which was reversed by a TLR4 inhibitor (Ma et al., 2017). It should be noted, however, 
that a 10-fold higher dose of all-thiol HMGB1 (compared to the dose of disulfide HMGB1) 
also induces mechanical hyperalgesia after intraplantar injection (Yamasoba et al., 2016).  
At the spinal level, injection of disulfide HMGB1 into the cerebrospinal fluid (but not all-
thiol HMGB1 or oxHMGB1) induces mechanical hypersensitivity, activation of glial cells 
and cytokine mRNA expression in a TLR4 dependent manner (Agalave et al., 2014). In 
addition to evoking pain-like behavior upon injection, the involvement of HMGB1 at the 
periphery and spinal level in different experimental pain models has been reported. In the 
collagen antibody-induced arthritis (CAIA) model, inflammation in the paw leads to 
increased levels of extra-nuclear HMGB1 in the lumbar spinal cord (Agalave et al., 2014) and 
blocking spinal HMGB1 action by the HMGB1 inhibitor (HMGB1 neutralization antibody 
and Abox peptide) reverses CAIA-induced mechanical hypersensitivity (Agalave et al., 
2014).  
Moreover, elevated levels of extra-nuclear HMGB1 in DRGs, spinal cord and sciatic nerve 
have been reported in different neuropathic pain models with induction of mechanical 
hypersensitivity (Spinal nerve ligation (SNL), Partial sciatic nerve ligation (PSNL), Tibial 
nerve ligation (TNI)) (Feldman et al., 2012; Nakamura et al., 2013; Shibasaki et al., 2010). 
Consistently, mechanical hypersensitivity induced by the different nerve injuries was 
reversed by treatment with the HMGB1 inhibitor, glycyrrhizin, (Feldman et al., 2012) and 
HMGB1 neutralizing antibodies (Nakamura et al., 2013; Shibasaki et al., 2010). In addition, 
mechanical hypersensitivity in a bone cancer experimental model (Tong et al., 2010), type 2 
diabetic-induce neuropathy model (P. C. Ren et al., 2012), cyclophosphamide induced 
bladder pain (Kouzoukas et al., 2016; Tanaka et al., 2014), Chemotherapy induced 
neuropathy (Nishida et al., 2016) and central stroke pain model (Harada et al., 2016b), is 
reversed by systemic treatment with a HMGB1 neutralizing antibody. Inhibiting endogenous 
HMGB1 with HMGB1 inhibitors shows reversal of pain-like behavior in different 
experimental pain model (Table 1). 
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Table 1. HMGB1 inhibition in different experimental pain model 
Pain model Species Sex Nociceptive 
assessment 
HMGB1 
inhibition 
Route of 
administration 
Reference 
Nerve injury pain model 
    SNL Rat Male VF, hotplate HMGB1 Ab Peri-sciatic (Shibasaki et al., 2010) 
   Nucleus pulposus Rat Female VF HMGB1 Ab i.p. (Otoshi et al., 2011) 
   TNI Rat Female VF Glycyrrhizin i.p. (Feldman et al., 2012) 
   Diabetes Mice - VF HMGB1 Ab i.t. (P. C. Ren et al., 2012) 
   PSNL Rat Male VF HMGB1 Ab i.v. (Nakamura et al., 2013) 
   PSNL Mouse Male VF HMGB1 Ab Perineural (F. F. Zhang et al., 
2015) 
Inflammatory pain model 
   LPS paw Rat  VF, thermal HMGB1 Ab i.pl. (Tanaka et al., 2013) 
   Arthritis Mouse Male, 
female 
VF HMGB1 Ab, 
Abox 
i.t. (Agalave et al., 2014) 
Other pain model 
   Bone cancer Rat Female VF HMGB1 Ab i.t. (Tong et al., 2010) 
   Cyclophosphamide 
induced bladder pain 
Mouse Female VF HMGB1 Ab, 
thrombomodulin 
i.p (Tanaka et al., 2014) 
   Chemotherapy induced 
neuropathy 
Rat Male VF, paw 
pressure 
HMGB1 Ab i.p. (Nishida et al., 2016) 
   Central post stroke pain Mouse Male VF HMGB1 Ab i.v., i.t (Harada et al., 2016a) 
   Cyclophosphamide 
induced bladder pain 
Mouse Female VF Glycyrrhizin i.p. (Kouzoukas et al., 
2016) 
 
1.5 SEX DIFFERENCE IN PAIN PROCESSING 
In the field of pain research, the importance of comparing mechanisms of nociception 
between males and females (both in rodents and patients) is currently gaining attention. From 
a preclinical perspective, Sorge et al. reported surprising data in 2011 suggesting that spinal 
TLR4 is important in inflammatory and neuropathic mediated mechanical hypersensitivity in 
male but not in female mice (Sorge et al., 2011). Later, it was shown that BDNF and 
purinergic receptor 4 (P2X4) in microglia are contributing to spared nerve injury (SNI) 
induced mechanical hypersensitivity in male but not in female mice. Moreover, it was 
indicated that in female mice, adaptive immune cells such as T-cells drive spinal 
sensitization, rather than microglia (Sorge et al., 2015). These findings have triggered many 
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researchers to explore sex-dependence of various pain-related mechanism in rodents, which 
have led to the insight that there is an underestimated complexity and discrepancy between 
studies associated with nociception and sex. For example, Sorge et al. reported that 
intrathecal injection of LPS induces mechanical hypersensitivity in male but not in female 
mice (Sorge et al., 2011). However, Woller et al. reported that intrathecal injection of LPS 
induces mechanical hypersensitivity equally in male and female mice and similarly, 
intrathecal injection of disulfide HMGB1 also induces mechanical hypersensitivity in male as 
well as in female mice (Agalave et al., 2014; Woller et al., 2016). However, sex differences 
were found after systemic treatment with the TLR4 antagonist (TAK-242) which reverses 
LPS-induced mechanical hypersensitivity in male but not in female mice (Woller et al., 
2016). Blocking the effect of spinal HMGB1 did not show a sex-dependent dimorphism in 
the CAIA model (Agalave et al., 2014), which opens the possibility that endogenous HMGB1 
may act on other receptors than TLR4 in some experimental models of pain. Moreover, 
formalin-induced allodynia (intraplantar injection) was delayed in both male and female mice 
after systemic treatment of TLR4 antagonist (TAK 242) and in TLR4 deficient mice (Woller 
et al., 2016), indicating that there may be differences in the sex-dependent engagement of 
TLR4 in nociception in the periphery compared to the spinal site.  
Sex dimorphism reported in terms of production of pro-inflammatory cytokines after immune 
challenge show that females produce higher levels than males. Based on the literature, 
differences in cytokine production between males and females are dependent on the disease 
model in rodents (Aulock et al., 2006; Drew & Chavis, 2000; Engler et al., 2016; Loram et 
al., 2012). One example is that, following Complete Freund’s Adjuvant (CFA) treatment, 
proinflammatory cytokines were highly elevated in trigeminal ganglia in male but not in 
female mice (Sorge & Totsch, 2017). Moreover, in the clinical field, LPS challenge in 
healthy humans elicits a higher cytokine production in the women compared to men 
(Karshikoff et al., 2015). Increases in the release of cytokines are correlated to higher 
hyperalgesia in females, as reviewed in Doyle and Murphy (2017). Cook, Nickerson and 
colleagues have shown that females develop more inflammation and hyperalgesia after 
immune challenges (CFA model) when compared to males (Cook & Nickerson, 2005). Thus, 
sex dimorphism mainly depends on the immune challenge and on the experimental disease 
model. 
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2 AIM OF THESIS 
The overall aim of the study was to investigate the role of HMGB1 in an arthritis-induced 
pain (model) and specifically explore the central and peripheral role of HMGB1 in pain 
processing. Three specific aims of this thesis were; 
1. Characterization of the collagen antibody-induced arthritis (CAIA) experimental 
model of arthritis as a model of arthritis-induced pain 
2. Investigation of the spinal role of HMGB1 in the CAIA model with particular focus 
on the HMGB1-Microglia-TLR4 axis 
3. Investigation of the peripheral role of HMGB1 in CAIA induced pain as a possible 
mechanism behind neuronal hypersensitivity 
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3 MATERIAL AND METHODS 
3.1 ANIMAL MODEL  
3.1.1 Animal 
All animal experiments were approved by and conducted according to the regulations of the 
local ethics committee for animal experiments in Sweden and in the US (Institutional Animal 
Care and Use Committee of The University of Texas at Dallas). All animals were housed in 
standard cages (4-5 mice/cage) in an environment maintaining 12 h light/dark cycle with food 
and water ad libitum. Different WT strains, genetically compromised mice (both male and 
female) were used for this thesis. For Paper I; CBA, QB and BALB/c male mice were used. 
For Paper II, BALB/c male and female were used for induction of CAIA. Genetically 
modified mice were used which have a deletion of TLR2, TLR4 and RAGE with a C57BL/6 
background. For Paper III, C57BL/6 male and female mice were used, and BALB/c and 
C57BL/6 male and female mice were used for Paper IV. Genetically modified and 
compromised mice, TLRfl/fl mice have been described previously (Jia et al., 2014). Mice with 
a TLR4 deletion in myeloid cells, or in peripheral nociceptors, were generated by crossing 
mice with the floxed TLR4 allele with mice expressing Cre under the control of the LysM or 
the Nav1.8 promoter, respectively. The resulting LysM-TLR4fl/fl and Nav 1.8-TLR4fl/fl and 
TLR4fl/fl (used as control mice) were backcrossed 8 generations to a C57BL/6 background at 
University of Texas at Dallas, US. 
3.1.2 Collagen antibody-induced arthritis model 
BALB/c male and female mice were injected intravenously with arthritogenic antibody 
cocktail (5 monoclonal CII antibodies), 1.25 mg/ mouse (Chondrex, Redmond, WA), on day 
0; synchronized with an intraperitoneal injection of LPS, 25 µg/ mouse (Chondrex, Redmond, 
WA), on day 5 to developed joint inflammation (Described detail in Paper I). Two different 
groups of control mice were used for this study; saline control mice received saline on day 0 
and on day 5 and LPS control mice received saline on day 0 with LPS on day 5. For this 
thesis work, the collagen antibody-induced arthritis model was used in Paper I, II and IV. 
3.1.3 Arthritis score and joint histology  
Clinical scores were measured by visual inspection of forelimbs and hind limbs. Clinical 
scores were allotted based on swelling and redness of toes, knuckles and ankle joints. An 
inflamed toe or knuckle gets 1 point, while an inflamed paw or ankle joint gets 5 points. Thus 
each limb gets a maximum of 15 points, and each mouse gets a maximum of 60 points. 
Clinical score data were plotted as arthritis score over time. Joint histology was performed on 
ankle joints, as we see the inflammation in the paw and ankle joint. Ankle joints were 
harvested during/after joint inflammation, post-fixed with 4% paraformaldehyde and 
decalcified for 3-4 weeks in decalcification solution (100 g EDTA, 
ethylenediaminetetraacetate, 75 g polyvinylpyrrolidone, 12.11 g Tris in 1 L Millique water 
adjusted to pH 7.0 with KOH (potassium hydroxide). After decalcification, ankle joints were 
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dehydrated using 70% ethanol and xylene followed by embedding in paraffin. Ankle joints 
were cut into 5 µm sections and mounted on glass slides and stained with hematoxylin and 
eosin staining. 
3.2 DRUGS AND DRUG DELIVERY 
3.2.1 HMGB1 inhibitor 
HMGB1 neutralizing antibody was used to block the action of endogenous HMGB1, the 
mouse anti-HMGB1 antibody (2G7) was injected spinally at a dose of 7.25 µg and 15 µg, and 
systemically injected as 100 µg. HMGB1 box A peptide (Abox) (20µg) was injected i.t. and 
300 µg injected systemically. The 2G7 anti-HMGB1 IgG2b noncommercial monoclonal 
antibody (mAb) (Chavan et al., 2012; Kokkola et al., 2003; Schierbeck et al., 2011) 
(developed at the former Critical Therapeutics, Boston, MA; now Cornerstone Therapeutics, 
Cary, NC) binds to an epitope within the amino acid region position 53 to 63 of the A box 
unit. Recombinant A box protein corresponds to 1 of the 2 highly conserved DNA binding 
domains of the HMGB1 protein (amino acid 1–89) and has been shown to block extracellular 
HMGB1 activities (Kokkola et al., 2003; Schierbeck et al., 2011). 
3.2.2 Microglia inhibitor 
The previously used microglial/glial inhibitor tetracycline antibiotic: minocycline was used 
for this study (Chen et al., 2017; Moller et al., 2016; Sorge et al., 2015). Minocycline was 
dissolved in saline and filter-sterilized with 0.22 mm millipore filter. The drug was freshly 
prepared and used within 3 days, because of its instability in solution. Minocycline was 
injected intrathecally (30 µg/mouse in 5 µl volume) whereas control mice were injected with 
5 µl of saline. 
3.2.3 Other drugs 
3.2.3.1 HMGB1 (different redox forms) 
Different redox forms of HMGB1 were used for the studies; the disulfide form of HMGB1 
(TLR4 ligand, cytokine-inducing form), the all-thiol HMGB1 (RAGE ligand, 
chemoattractant form) and the oxidized form of HMGB1 (no known biological activity). In 
Paper II and Paper III, intrathecal delivery of the different forms (1 µg/mouse) was 
performed to investigate the central role of HMGB1 in pain processing. In Paper IV, intra-
articular injection of disulfide HMGB1 and all-thiol HMGB1 was done to investigate the 
peripheral role of HMGB1 in pain processing. 
3.2.3.2 Buprenorphine 
Buprenorphine is a semisynthetic derivative of theabaine with mixed partial agonist opioid 
receptor modulator. Buprenorphine is well known to have high affinity towards E opioid 
receptors with antagonizing property. It has an inhibitory action on voltage-gated sodium 
channels with binding to the anesthetic binding site and has a local anesthetic property. 
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3.2.3.3 Pentoxifylline 
Pentoxifylline is a xanthine derivative drug used to treat muscle pain in peripheral artery 
disease. It is a competitive phosphodiesterase inhibitor, which increases the intracellular 
levels of  cAMP and activates PKA, which leads to inhibition of TNF and leukotriene 
synthesis and reduces inflammation. Systemic injection of pentoxifylline was performed in 
the inflammatory and late phase of CAIA model. 
3.2.3.4 Gabapentin 
Gabapentin is currently used in the clinic to treat neuropathic pain and seizures. It interacts 
with voltage-gated calcium channels, binding the α2δ subunit of the channel, which leads to a 
reduction in calcium current. 
3.2.3.5 Diclofenac 
Diclofenac is a non-steroidal anti-inflammatory drug commonly used to treat inflammation 
and used as an analgesic drug. The mechanism of action of diclofenac is to inhibit 
cyclooxygenase II. 
Table 2. List of the different categories of drugs, with route and dose 
Drug Study Paper Route Dose 
2G7 Central Paper II  i.t. 15 µg / mouse 
2G7 Peripheral Paper III s.c. 100 µg / mouse 
Abox Central Paper II  i.t 20 µg / mouse 
all-thiol HMGB1 Central/peripheral Paper II/IV i.t. /i.a. 1 µg /mouse 
Buprenorphine CAIA Paper I i.p. 0.1 mg/KG 
Diclofenac CAIA Paper I i.p. 30 mg/KG 
disulfide HMGB1 Central/peripheral Paper II/III/IV i.t. /i.a. 1 µg /mouse 
Gabapentin CAIA Paper I i.p. 100 mg/KG 
Minocycline Central Paper III i.t 30 µg / mouse 
oxHMGB1 Central Paper II i.t. 1 µg /mouse 
Pentoxifylline CAIA Paper I i.t. 30 µg / mouse 
 
3.3 ASSESSMENT OF PAIN BEHAVIOR 
3.3.1 Von Frey measurement 
For measurement of mechanical hypersensitivity (pain-like behavior), the von Frey test was 
used. It is described in greater detail in Paper I, II III and IV. Briefly, animals were 
acclimatized to the Von Frey station on two different occasions. Three baseline 
measurements were performed on different days, followed by randomization of mice into the 
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different treatment groups. Mechanical hypersensitivity was measured by the assessment of 
paw withdrawal threshold in response to application of von Frey optihair filament, using the 
up-down method (Chaplan et al., 1994). A series of von Frey filaments with a logarithmically 
incremental stiffness of 0.5, 1, 2, 4, 8, 16, and 32 mN (converted to 0.051g, 0.102g, 0.204g, 
0.408g, 0.815g, 1.63g, and 3.26g, respectively) were applied to the plantar surface of the hind 
paw and held for 2 to 3 seconds. Tissue damage was avoided by setting 4 g as a cutoff. 
Withdrawal of the hind paw was noted as a positive response. For the CAIA animal model 
and the intrathecal HMGB1 model withdrawal thresholds from both hind paws were 
averaged. However, in the peripheral project, only withdrawal thresholds of the injected 
(ipsilateral hind) paw were considered for the analysis. Data were plotted as 50% probability 
for withdrawal thresholds (which is the force of the filament to which an animal reacts to 
50% of the presentations) expressed as the thresholds in gram. 
3.4 PCR 
3.4.1 On spinal cord 
In Paper II, animals were deeply anesthetized with 4% isoflurane followed by decapitation. 
Lumbar spinal cord was dissected with laminectomy method with L3-L5 region collected. 
Tissues were flash frozen and stored in -70⁰ C until use for the analysis. Spinal cord tissues 
were homogenized in Trizol with tissue lyser (25 Hz frequency for 2 min with 2 cycles; 
QAIGEN). mRNA was extracted according to the manufactures protocol, using TRIzol. 
Reverse transcription of RNA followed to make complementary DNA, which was further 
used in real time qualitative polymerase chain reaction (Step-one system, Applied biosystem, 
Foster city, CA). Below is the list of Taqman primer probes (Table no. 2) that were used. 
Table 3. List of the Taqman primer probes 
Analyte Taqman primer Name of analyte 
Tnf Mm00443258_m1 Tumor necrosis factor 
IL1β Mm00434228_m1 Interleukin 1 beta 
Il6 Mm00446190_m1 Interleukin 6 
MCP-1 Mm00441242_m1 Monocyte chemoattractant protein 1 
Cxcl1 Mm04207460_m1 Chemokine (C-X-C motif) ligand 1 
Cxcl2 Mm00436450_m1 Chemokine (C-X-C motif) ligand 2 
Ngf Mm00443039_m1 Nerve growth factor 
Cox2 Mm00478374_m1 Cyclooxygenase 2 
Cd11b Mm00434455_m1 Cluster of differentiation molecule 11B 
Gfap Mm00546086_m1 Glial fibrillary acidic protein 
Hmgb1 Mm00849805_gH High mobility group box 1 protein 
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Hprt-1 Mm01545399_m1 Hypoxanthine phosphoribosyltransfarase 1 
 Pes-1 Mm00727566_s1 Pescadillo homolog 1 
 
3.4.2  On ankle joint 
 In Paper IV, mice were injected intra-articularly with disulfide HMGB1 and all-thiol 
HMGB1, 4 hours later animals were deeply anesthetized with 4% isoflurane followed by 
decapitation. Ankle joints were dissected and trimmed as 6mm from ankle joint to tibia and 
paw, samples were flash frozen and stored in -70⁰ C until further processing. Joint tissue was 
pulverized with biopulveriser followed with RNA extraction with TRIzol using tissue lyser 
(30 Hz frequency for 2min with 2 cycles, QAIGEN). Reverse transcription were performed to 
make cDNA followed with real time quantitative PCR (Step one System, Applied Biosystem, 
Foster city, CA). 
 
3.5 IMMUNOHISTOCHEMISTRY 
For immunohistochemistry, animals were anesthetized with isoflurane and intracardially 
perfused with saline/PBS solution followed by 4% paraformaldehyde (PFA). The Lumbar 
spinal cord tissue (L1-L6) and DRG tissue (L3-L5) was dissected, postfixed in 4% PFA for 
12-20 h and cryoprotected in 20% sucrose. Lumbar spinal cord tissue (L3-L5) and DRG were 
immersed in OCT on filter paper, which were expose to CO2 stream. Spinal cord tissue was 
cut in 20 µM section and mounted on glass slide. Mounted sections were pre-incubated with 
5% normal goat or donkey serum in 0.2% Triton X-100 in PBS solution to block nonspecific 
binding for antibodies. Consequently, sections were incubated with the primary antibodies 
overnight at 4 ⁰C. After primary antibody treatment sections were incubated in respective 
secondary antibody then stained sections were coverslipped with prolong gold antifade 
medium with DAPI (Life technologies) and examined in Zeiss LSM710 confocal 
microscope. 
Table 4. List of the Primary antibody with its dilution  
Primary Antibody Vendor Catalog number Dilution 
Rabbit anti-HMGB1 Abcam Ab18256 1:500 dilution 
Mouse anti-NeuN Millipore MAB377 1:1000 dilution 
Anti-NeuN-Alexa 488 Millipore MAB377x 1:100 dilution 
Mouse anti-GFAP Millipore MAB 360 1:1000 dilution 
Goat anti-Iba1 Abcam Ab107159 1:2000 dilution 
Rabbit anti-Iba1 Wako 01919741 1:2000 dilution 
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3.6 WESTERN BLOT 
Western blot protocol details are described in Paper II. Briefly, mice were anesthetized, and 
spinal cord tissues was harvested by hydro-extrusion and immediately flash-frozen on dry ice 
and stored at -70°C until analysis. NE-PER (nuclear and cytoplasmic kit, Thermo Fisher 
Scientific, Lafayette, CO) was used to extract total protein from nucleus and cytoplasm 
(extranuclear). Total protein was separated by gel electrophoresis (NuPAGE 4–12% Bis Tris 
and MES running buffer, Invitrogen) and wet transferred to nitrocellulose membrane 
(Invitrogen). Membranes with separated protein were treated with 5% low-fat milk in Tris-
based buffer (50 mmol/L Tris–HCl and 6 mmol/L NaCl with 0.1% Tween 20) to avoid 
nonspecific binding sites.  
Blocked membranes were incubated with primary antibody overnight (48 hours for 2G7), 
followed by incubation in the secondary antibody conjugated to horseradish peroxidase 
(1:7500, Cell Signaling Technology, Danvers, MA). To visualize protein-antibody complex, 
chemiluminescent reagents (Supersignal, Pierce, Rockford, IL) were used, and signal 
intensity was measured using Quantity One software (Bio-Rad, Hercules, CA). Stripping 
solution (1X) were used to remove the antibodies (Millipore, Billerica, MA), in case the 
membranes were to be reprobed with different antibodies. Positive bands were normalized to 
their respective GAPDH band. Primary antibodies used for this study were 2G7 mouse anti-
HMGB1 (1:1000; 1.2 µg), mouse anti-TATA binding protein (1:2000, catalog no. 051531, 
Millipore, Billerica, MA), rabbit anti-histone (1:5000, catalog no. ab1791, Abcam, 
Cambridge, UK), and mouse anti-GAPDH (1:10,000, catalog no. ab8245, Abcam). Data were 
analyzed and expressed as percentage change of control. 
3.7 LIQUID CHROMATOGRAPHY- MASS SPECTROMETRY (LCMS/MS)  
LCMS/MS analysis was performed to investigate different regulation of protein profile in 
male and female mice intrathecally injected with minocycline and saline; those previously 
injected with disulfide HMGB1. Total protein was extracted from the spinal cord collected at 
6h after minocycline treatment with lysis buffer (1X PBS with 1% SDS + cocktail of protease 
inhibitor) with repetitive freeze/thaw process with sonication for 10-15 sec (0.3s on/0.7s 
pulse) using a tip sonicator. Total protein concentration was assessed using standard BCA 
method from Pierce. Alkylation and reduction of the protein were done by addition of 
dithiothreitol (DTT) and incubating at 56 °C for 30 min followed by addition of 25 mM 
iodoacetamide (IAA) and incubating for 30 min at 37 °C in dark. Acetone precipitation was 
done overnight to precipitate proteins. Digestion buffer (50 mM triethylammonium 
bicarbonate (TEAB) at pH 8.0 approx.) was used to resuspend the pellets. Combination of 
endoproteases Lys-C and trypsin to each sample vial at an E:S ratios of 1:50 and 1:100 
respectively was done for enzymatic digestion. The samples were incubated overnight at 37 
°C with shaking at 500 rpm. Prepared samples were run on TMT6 plex plate and labeling was 
performed according to standard protocol. Sample preparation and data analysis is described 
in detail in Paper III.  
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3.8 STATISTICAL ANALYSIS 
For the statistical analysis, two-way analysis of variance (ANOVA) was used to compare 
changes over the time followed by the Bonferroni post hoc test. Comparisons of three or 
more groups were performed with one-way ANOVA followed by the Bonferroni post hoc 
test. Differences between two separate groups were performed using the student’s t-test. 
Clinical scores (the arthritis scores) were compared using Kruskal-Wallis test, followed by 
Dunn’s multiple comparisons post hoc tests. All data are presented as the mean ± standard 
error of the mean. Statistical significance was reported as *p<0.05, **p<0.01 and 
***p<0.001. All statistical tests were performed using the Graph Pad prism-6 software 
(SanDiego, CA, US).  
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4 RESULTS 
4.1  COLLAGEN ANTIBODY-INDUCED ARTHRITIS (CAIA) 
For this thesis, We first characterized and then used the CAIA model as a model for arthritis-
induced pain.  
4.1.1 CAIA induces transient inflammation but persistent mechanical 
hypersensitivity in male and female mice 
Three different mouse strains were used to investigate CAIA-induced joint inflammation and 
mechanical hypersensitivity. Intravenous injection of a cocktail of collagen type II antibodies 
followed by a low dose of intraperitoneal LPS induced transient joint inflammation and 
persistent mechanical hypersensitivity in QB, CBA, BALB/c mice. Though some variation in 
the temporal profile and degree of disease severity (Paper I, Fig.1) a transient inflammation 
with persistent mechanical hypersensitivity was observed in all three strains of mice. The 
model was divided into two different phases based on the resolution of visual signs of joint 
inflammation such that we refer to the inflammatory phase (flare of joint inflammation) and 
post-inflammatory phase or late phase (after resolution of inflammation with pain-behavior 
still detectable). For further studies in this thesis utilizing the CAIA model, BALB/c mice 
were used.  
4.1.2 CAIA induces histopatholopathological changes in the ankle joint  
To assess the degree of joint pathology subsequent to CAIA, joint histology was performed 
on ankle joints from three different mouse strains collected during the inflammatory and late 
phase. We found synovitis, bone erosion and cartilage destruction during the inflammatory 
phase and signs of residual bone erosion in the late phase in all three strain (Figure 8). 
          
Figure 8.  Joint histopathological changes in collagen antibody–induced arthritis (CAIA) male mice with 
hematoxylin and eosin staining for A) QB mouse strain, B) CBA mouse strain and C) BALB/c mouse strain. Bar 
graph represents synovitis, bone erosion and cartilage destruction for respective mouse strains (From Paper I, 
Fig 2) 
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4.1.3 Hypersensitivity in the two different phases of the CAIA model are 
maintained by different mechanisms 
In order to investigate if the hypersensitivity in the two different phases in CAIA model are 
mediated by the same mechanisms we took a pharmacological approach and used different 
categories of conventional analgesic drugs. The outcome of these experiments is summarized 
in Table 5. Systemic injection of buprenorphine (weak partial µ-opioid receptor agonist) and 
gabapentin (voltage-gated calcium channel inhibitor) reverses CAIA induced mechanical 
hypersensitivity in inflammatory as well as in late phase. Interestingly, systemic injection of 
diclofenac (COX1/2 inhibitor) reverses CAIA induced hypersensitivity in inflammatory but 
not in late phase. Similarly, systemic injection of etanercept (soluble decoy TNF receptor) 
shows the same pattern as diclofenac (Bas et al., 2016). 
Table 5. Pharmacological profiles of known analgesic and anti-inflammatory on CAIA induced inflammatory 
and late phase hypersensitivity in male mice. + Represents reversal of CAIA induced mechanical 
hypersensitivity and – represents, no effect on CAIA induced hypersensitivity (Summarized from Paper I). 
Drug  Category Inflammatory Phase Late Phase 
Diclofenac NSAIDs + - 
Buprenorphine 
 
 
non-selective, mixed agonist–
antagonist opioid receptor 
modulator 
+ + 
Gabapentin voltage gated calcium ion 
channel inhibitor 
+ + 
 
4.1.4 CAIA induces spinal glial cell activation during and after joint 
inflammation 
It is well established that, spinal glial cells play an important role in maintenance of pain in 
different experimental models of chronic pain. To investigate if a flare of joint inflammation 
has an effect on spinal glial cells in the inflammatory and late phase, we performed 
immunohistochemistry on lumbar spinal cord tissue using antibodies against Iba1 (microglia 
marker) and GFAP (astrocyte marker). In mice subjected to CAIA, we found a significant 
increase in the signal intensity for both the microglial and astrocytes markers, but with some 
strain differenece. In QB mice microglia as well as astrocyte were significantly elevated in 
both phases. However, in CBA mice microglia staining was significantly increased in both 
phases while astrocytes were activated only in the late phase (Paper I, Fig 4 and Fig 5).  
4.2 SPINAL ROLE OF HMGB1 IN ARTHRTIS INDUCED PAIN 
In Paper II and Paper III, the CAIA model was used to investigate the role of spinal 
HMGB1 in arthritis-induced mechanical hypersensitivity. Furthermore, the relationship 
between the redox state of HMGB1 and its pronociceptive properties was examined.  
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4.2.1 HMGB1 is constitutively expressed in spinal neuron, microglia and 
astrocytes 
In order to examine if HMGB1 is present in the lumbar spinal cord, we performed 
immunohistochemistry using anit-HMGB1 antibodies and co-localized the immunoreactivity 
with different cell markers such as NeuN (neuronal marker), Iba1 (microglia marker) and 
GFAP (astrocyte marker). We found HMGB1 constitutively expressed in naive spinal cord 
colocalizing with neurons, microglia and astrocytes (Figure 9). 
                
Figure 9. Immunohistochemistry for HMGB1 in neurons, microglia, and astrocytes in the dorsal horn of lumbar spinal cord. 
Panel A, B: HMGB1 co-localize with NeuN marker Panel C,D): HMGB1 cololize with IBA1 marker (microglia) Panel EF) 
HMGB1 cololize with GFAP marker (astrocytes). Scale bars are 50 µm (upper panels) and 10 µm (lower panels). 
Micrographs are single optical sections of the medial lumbar dorsal horn obtained with 20X(upper panels) or 40X (lower 
panels) objectives (From Paper II, Fig 3) 
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4.2.2 CAIA increases spinal HMGB1 mRNA levels in both phases and 
HMGB1 protein levels during joint inflammation 
To investigate if CAIA-induced peripheral joint inflammation has an effect on HMGB1 
expression in the spinal cord, we assessed HMGB1 mRNA levels by qPCR and protein levels 
by western blot. Spinal Hmgb1 mRNA levels were significantly elevated in the CAIA group 
as compared to saline and LPS (control) group in both the inflammatory and the late phase 
(Paper II, Fig 4A, B). As extracellular HMGB1 has the capacity to function as a DAMP, we 
assessed the extranuclear levels of HMGB1 and found significantly increased levels of 
extranuclear HMGB1 in spinal cords from mice subjected to CAIA compared to saline and 
LPS control mice in inflammatory phase, but no difference between the groups in the late 
phase (Figure 10).  
                      
Figure 10. Spinal extranuclear HMGB1 elevated in CAIA inflammatory phase but not in late phase as compared 
to saline and LPS control. Density of HMGB1 signal was normalized against GAPDH and the data expressed as 
percentage of the saline control group. Histone was used as a negative control for extra nuclear fractionation 
(From Paper II, Fig 4). 
4.2.3 Intrathecal injection of HMGB1 induces pain like behavior in male and 
female mice in a redox state dependent manner 
To investigate if elevated level of extranuclear HMGB1 contributes to nociception we 
injected different redox form of HMGB1 intrathecally and measured mechanical 
hypersensitivity. Significant reductions of the mechanical thresholds were found in 
male and female BALB/c and C57BL/6 mice after a single intrathecal delivery of 
disulfide HMGB1. No change in mechanical threshold was observed in mice injected 
intrathecally with all-thiol HMGB1 or oxidized HMGB1. The mechanical 
hypersensitivity induced by disulfide HMGB1 lasted for approximately 4 days in 
male mice, while female mice recovered somewhat faster. Hyperalgesic index data 
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were calculated for day 0 to day 3 for respective study (Figure 11).
 
Figure 11. Single spinal injection of disulfide HMGB1 induces mechanical hypersensitivity in C57BL/6 and 
BALB/c male and female mice. Disulfide but not all thiol and oxidized HMGB1 induced mechanical 
hypersensitivity in C57BL/6 male mice. Hyperalgesic index calculated for 0-3 days. Data are presented as mean 
± standard error of the mean, males: n = 6 mice per group; females n = 12 mice per group (From Paper II, Fig 
5). 
4.2.4 Disulfide HMGB1 mediate pain like behavior and induction of cytokine 
and glial cell associated mRNA via TLR4 
To examine through which receptor disulfide HMGB1 initiate pro-nociceptive effect in naïve 
mice, we used genetically modified mice with deletion of some, but not all, receptors 
HMGB1 is thought to at through; TLR2, TLR4, and RAGE. Single intrathecal injection of 
disulfide HMGB1 led to a reduction in mechanical threshold in TLR2 and RAGE KO mice 
but not in TLR4 KO mice. Further, we investigated the expression level of cytokines, 
chemokine and glial markers after intrathecal injection of HMGB1. Disulfide HMGB1 but 
not all-thiol HMGB1 induced cytokine (Tnf and Il1-β) and chemokine (Ccl2, Cxcl1 and 
Cxcl2) expression in WT male mice but not in TLR4 KO mice (Figure 12). Similar to 
cytokine and chemokine factors, glial factors such as (Gfap: astrocyte marker and Cd11b: 
microglia marker) were significantly elevated in after single intrathecal injection of disulfide 
HMGB1 in WT male mice but not in TLR4 KO mice (Paper II, Fig 7). 
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Figure 12. Single spinal injection of disulfide HMGB1 induces mechanical hypersensitivity in Tlr2-/- and Rage-/-, 
but abrogated in Tlr4-/- mice. Hyperalgesic index calculated for 0-3 hours. Data are presented as mean ± standard 
error of the mean (From Paper II, Fig 6). 
4.2.5 Blocking spinal HMGB1 reverses CAIA induced hypersensitivity during 
and after join inflammation in male and in female mice 
To investigate if an elevated level of spinal HMGB1 contributes to the induction of 
mechanical hypersensitivity in the CAIA model we used HMGB1 inhibitors such as HMGB1 
neutralization antibody (2G7) and Abox peptide (Abox). The HMGB1 inhibitors were 
injected intrathecally during the inflammatory and late phase, in male and female CAIA 
mice. We found that repetitive intrathecal delivery of the HMGB1 inhibitors reversed CAIA 
induced mechanical hypersensitivity during the inflammatory and late phase, in both male 
and female mice (Figure 13). 
 
Figure 13. Repetitive intrathecal injection of 2G7 and Abox reverse collagen antibody-induced arthritis (CAIA)-
induced mechanical hypersensitivity during the inflammatory and the late phase in male as well as in female 
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mice. Data are presented as mean ± standard error of the mean, males n = 6-8 mice/ group and females n= 6-8 
mice/ group) (From Paper II, Fig 2). 
4.3 SEX-DEPENDENT SPINAL HMGB1-TLR4-MICROGLIA INTERACTION FOR 
MAINTANANCE OF PAIN 
Growing evidence shows sex dependence of spinal glial cells in maintenance of neuropathic 
and inflammatory pain (Chen et al., 2017; Sorge et al., 2015). This study (Paper III) was 
intended to examine if the pronociceptive property of disulfide HMGB1 display sex 
dimorphism. 
4.3.1 Intrathecal injection of disulfide HMGB1 induces microglia activation in 
male and female mice 
To investigate if disulfide HMGB1 shows a sex dependent effect on spinal microglia we 
assessed Iba1 signal intensity in the lumbar spinal 24 h after intrathecal delivery of disulfide 
HMGB1 in male and female mice. We found significantly increased Iba1 signal intensity of 
both male and female mice compared to respective control (Figure 14). 
          
Figure 14. Spinal microglia reactivity in the lumbar level of spinal cord after intrathecal delivery of disulfide 
HMGB1. Immunoreactivity for IBA1 in A) male and B) female mice after 24 h post injection of disulfide 
HMGB1. Bar graph represents percentage signal intensity for IBA1 in C) male and D) female. Data are 
presented as mean ± standard error of the mean, males n = 5-6 mice/ group and females n= 5-6 mice/ group 
(From Paper III, Fig 2)  
4.3.2 Blocking spinal microglia activity with minocycline reverses disulfide 
HMGB1 mediated hypersensitivity in male but not in female mice 
As recent data point to a sex-associated contribution of microglia to spinal signal 
transmission (Chen et al., 2017; Sorge et al., 2015; Taves et al., 2016) we investigated if 
disulfide HMGB1 mediated hypersensitivity is microglia dependent in male and/or female. 
To assess this, we injected minocycline, commonly used as a microglia inhibitor, in male and 
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female mice together with and following intrathecal injection of disulfide HMGB1 and 
assessed mechanical hypersensitivity at 3 and 6h and after injections We found that 
minocycline significantly prevented and reversed disulfide HMGB1-mediated 
hypersensitivity at the 6 h time point in male but not in female mice (Figure 15). This data 
suggest that disulfide HMGB1-mediated hypersensitivity is dependent on microglia in male 
but not in female mice.  
 
Figure 15. Intrathecal injection minocycline reverses disulfide HMGB1 induced mechanical hypersensitivity in male but not 
in female mice. Bar graph represents withdrawal threshold prior to and 6h after injection of HMGB1+minocycline or 
HMGB1+ vehicle on day 1 for A) male and C) female mice. On day 2, 24 hr after HMGB1+minocycline/vehicle injection 
withdrawal threshold were measured again, and minocycline and vehicle injected intrathecally a second time, and mechanical 
hypersensitivity assessed 6 hr later in B) male and D) female mice. Data presented as mean ± standard error of the mean. 
*p<0.05, **p<0.01 (From Paper III, Fig 3). 
4.3.3 Sex dimorphism in response to minocycline using deep protein 
analysis 
Mass spectrometry was used to investigate differences in the global protein expression in 
male and females injected with disulfide HMGB1 and vehicle (HMGB1 only) or minocycline 
treatment. We identified relatively quantified 2947 proteins. Using 2x2 factorial design, we 
found that male and female mice subjected to disulfide HMGB1 only, or in response to 
minocycline treatment showed differential regulation of 54 protein (q value < 0.05) 
(Supplementary table 1). Out of 54 proteins, 36 proteins showed the difference in regulation 
between male and females only injected with disulfide HMGB1. Surprisingly, 44 proteins 
showed differential regulation in males after treatment with minocycline, but only eight in 
females (7 protein of these showed differential regulation in males) (Supplementary Table 1). 
Intercept between 36 and 44 protein above was 26 proteins. In addition, and in line with male 
dependent differential regulations, 12 proteins showed the statistical significant interaction 
between gender difference and the addition of minocycline (Supplementary table 1).  
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All these protein results point at clear treatment effect of minocycline in males, with minor 
effect in females. Serine protease inhibitor 1-5 (A1AT5) was the protein with the largest 
difference between male and female after injection of HMGB1 only (Figure 16A). The 
proteins with the largest difference in response to minocycline treatment in male mice were 
alpha 1 antitrypsin 1-5 (A1AT5) (Figure 16A), serine protease inhibitor A3K (SPA3K) 
(Figure 16D) and haptoglobin (HPT) (Figure 16F), of which none of them showed a 
significant treatment effect in female.  
 
Other serine family members alpha-1-antitrypsin 1-2 (A1AT2), Alpha-1-antitrypsin 1-4 
(A1AT4) and serine protease inhibitor A3N (SPA3N) (Figure 16B, C, E) showed statistically 
significant increased in expression in males treated with minocycline but did not find 
treatment effect in females. Addition to other proteins, Vitamin D binding protein (VDBP) 
(Figure 16G) and hemopexin (Figure 16H) are other examples of proteins which showed 
statistically significant increased in expression in response to minocycline treatment in males, 
but not females. 
 
 
 
 
Figure 16. Depth protein analysis in male and female mice after treatment of minocycline (From Paper III, 
Fig 5). 
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4.4 PERIPHERAL ROLE OF HMGB1 IN ARTHRTIS INDUCED PAIN  
The role of of HMGB1 the joint during arthritis-induced pain and the importance of the redox 
state of HMGB1 and interaction with TLR4 have been investigated in detail in Paper IV.  
4.4.1 Systemic injection HMGB1 inhibitor reverses CAIA induced pain like 
behavior in male but not in female mice 
To investigate if blocking peripheral HMGB1 shows sex dimorphism in CAIA-induced 
mechanical hypersensitivity, we injected the HMGB1 neutralizing antibody 2G7 systemically 
from day 12 to day 17 after injection of collagen type II antibodies. Interestingly, while 
blocking the action of HMGB1 did not alter the degree of arthritis, we found that 2G7 
reversed CAIA-induced mechanical hypersensitivity in male mice but not in female mice 
(Figure 17). 
          
Figure 17. Repetitive systemic injection of HMGB1 inhibitor reverses CAIA induced hypersensitivity in A) 
male but not in B) female mice in inflammatory phase (From Paper IV, Fig 2).  
4.4.2 Intraarticular injection of disulfide HMGB1, but all-thiol HMGB1 
induces hypersensitivity in male as well as female mice with induction 
of cytokine and chemokine expression 
To investigate if presence of HMGB1 in the joint induces hypersensitivity in a sex and redox 
state dependent fashion, we inject different redox form of HMGB1 in male and female naïve 
mice. Intra-articular injection of disulfide HMGB1 and all-thiol HMGB1 were performed in 
male and female mice C57/BL6 and BALB/c mice. We found that disulfide HMGB1 but not 
all-thiol HMGB1 induced hypersensitivity in BALB/c and C57BL/6 male and female mice 3 
and 6 hours after injection (Figure 18). We found a significant increase in mRNA levels of 
cytokines (Tnf, Il1-β and Il6), chemokines (Ccl2, Cxcl1 and Cxcl2) and other pain-associated 
factors factors (Ngf and Cox2) in disulfide HMGB1-injected ankle joint but not in all-thiol 
HMGB1 injected mice. Comparing male to female mice showed that disulfide HMGB1-
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induced cytokine-chemokine expression was more prominent in male mice compared to 
female mice (Figure 19). 
 
Figure 18. Single intraarticuar injection of disulfide HMGB1 but not all-thiol HMGB1 induces mechanical 
hypersensitivity in male and female mice in two different strains (A-F). Hyperalgesic index calculated for 0-6 h 
for C57BL/6 A) male and B) female and BALB/c C,E) male and D,F) female mice (From Paper IV, Fig 3). 
         
Figure 19 Expression of cytokine (A-C), chemokine (D-F), Other factors (G-H) and immune cells (I-K) in ankle 
joint injected with disulfide HMGB1 in C57BL/6 male and female mice (From Paper IV, Fig 4).  
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4.4.3 Disulfide HMGB1 mediated hypersensitivity is induced by TLR4 
expressed both on nociceptors and myeloid cells in male and female 
mice, but with a more pronounced immune cell contribution in male 
mice 
To examine if disulfide HMGB1 induces mechanical hypersensitivity via TLR4 on peripheral 
neurons or local myeloid cells genetically modified mice were used. These mice had a 
deletion of TLR4 in Nav1.8 positive peripheral neurons (Nav1.8-TLR4fl/fl) or myeloid cells 
(LysM-TLR4fl/fl).  TLR4fl/fl mice were used as a WT control. At the 6-hour time-point female 
Nav1.8-TLR4fl/fl mice were completely, whereas Nav1.8-TLR4fl/fl male mice were partially 
protected from the development of hypersensitivity after intra-articular injection of disulfide 
HMGB1 (Figure 20A, B). Both male and female LysM-TLR4fl/fl mice were protected from 
disulfide HMGB1-induced hypersensitivity at the 6-hour time point. However, female LysM-
TLR4fl/fl mice were not protected against disulfide HMGB1 induced mechanical 
hypersensitivity at the 3-hour time point, though it should be noted that TLR4fl/fl (WT) mice 
injected with disulfide HMGB1 did not show reduction in withdrawal thresholds at the 3-
hour time point in female mice. Moreovr, LysM-TLR4fl/fl male mice were protected from 
disulfide HMGB1-induced hypersensitivity at all time points. This data suggest that disulfide 
HMGB1 mediated mechanical hypersensitivity induced by TLR4 expressed both on 
nociceptors and myeloid cells in male and female mice, but with a more pronounced immune 
cell contribution in male and neuronal contribution in female mice (Figure 20C, D). 
            
Figure 20 Disulfide HMGB1 induces hypersensitivity in male and female WT mice, whereas Nav1.8 TLR4fl/fl 
female completely protected and Nav.1.8 TLR4fl/fl male partially protected after injection into ankle joint (A, B). 
LysM TLR4fl/fl male but not LysM TLR4fl/fl and WT were protected from disulfide HMGB1 induced 
mechanical hypersensitivity (C,D) (From Paper IV, Fig 5, 6). 
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5 DISCUSSION 
 
The aim of this thesis was to advance our understanding of the DAMPs molecule HMGB1 
and if and how it is involved in spinal and peripheral mechanisms of pain signal transduction 
and transmission, with a specific focus on the arthritis-induced pain. This study points to an 
intriguing role of disulfide HMGB1 both in the joint and the spinal cord in arthritis-induced 
pain and that the redox state of HMGB1 is critical in this process. To our surprise, we found a 
sex- and cell type-dependent coupling between the pronociceptive properties of disulfide 
HMGB1 and activation of TLR4.  
In Paper I, the CAIA model was characterized from a pain perspective. Collagen antibodies 
were injected intravenously against a collagen type II epitope that is shared between rodents 
and humans, synchronizing with an intraperitoneal injection of LPS to increase the incidence 
and severity of disease (Nandakumar et al., 2003). Previous work has shown that both 
systemic and intrathecal injection of LPS induces pain like behavior (Christianson et al., 
2011; Maier et al., 1993; Meller et al., 1994) and glial cell activation in the spinal cord in 
rodents (Guo & Schluesener, 2006). However, the dose used in our study was a subthreshold 
dose of LPS, which does not have effect on pain-like behavior and on glial activation at 
spinal level. Mice subjected to CAIA displayed transient inflammation but a long-lasting 
hypersensitivity in three different mouse strains with alterations in joint histopathology. 
Similarly, also in another passive model of arthritis, the K/BxN serum transfer model (naïve 
mice injected i.p. with polyclonal serum containing anti-glucose-6-phosphate isomerase 
antibody) transient joint inflammation with long-lasting hypersensitivity was observed 
(Christianson et al., 2010) indicating that an episode of antibody-driven joint inflammation 
has long-term consequences on neuronal excitability. Interestingly, the pharmacological 
profile achieved using antinociceptive and anti-inflammatory drugs reveals that CAIA-
induced hypersensitivity is driven via different mechanisms at different stages of the disease. 
Blocking cyclooxygenase 1/2 activity and the action of TNF (Bas et al., 2016) during joint 
inflammation, but not after resolution of joint inflammation, reverses CAIA-induced 
mechanical hypersensitivity; which indicated that prostaglandins and TNF play an important 
nociceptive role during joint inflammation, but there is a temporal shift in the mechanism 
maintaining the hypersensitivity. Moreover, gabapentin (approved for the treatment of 
neuropathic pain) reverses CAIA and K/BxN-induced hypersensitivity during both phases. 
Also, factors such as activating transcription factor 3, alpha-2-delta and galanin, associated 
with nerve injury, are elevated in DRG neurons in the late phase of the CAIA and/or K/BxN 
model (Su et al., 2015, Christianson et al., 2010). Thus it is possible that changes that have 
some aspects in common with neuropathic pain are activated after antibody-induced joint 
inflammation. Clearly, the CAIA model is an interesting model for investigation of the spinal 
and peripheral role of HMGB1 in arthritis-associated pain. 
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In Paper II and III, we explored the role of extranuclear HMGB1 in the spinal cord and how 
the different redox states of HMGB1 contribute to pain signal processing. In Paper II, we 
examined the presence of HMGB1 in different cell types at the spinal level. In agreement 
with previously reported findings in rats (Feldman et al., 2012; Nakamura et al., 2013; 
Shibasaki et al., 2010), we found constitutive expression of HMGB1 in spinal neurons, 
astrocytes and microglia in mice. Importantly, the extranuclear levels of HMGB1 were found 
to be elevated at the lumbar level of spinal cord subsequent to induction of CAIA indicating 
that peripheral joint inflammation leads to the spinal release of HMGB1 (Figure 21). This 
notion is further supported by the analgesic effect of spinal injection of an HMGB1 
neutralizing antibody, which most likely is exerting its action by binding extracellular 
HMGB1 and thereby preventing the actions of HMGB1. Since HMGB1 is expressed in both 
neurons and glial cells, we cannot draw any conclusions about which cell type is the source of 
the extranuclear HMGB1. However, mounting data suggest that HMGB1 translocate from 
the nucleus to the cytoplasm in the dorsal root ganglions (DRGs) and dorsal horn neuron 
subsequent to the nerve ligation (Feldman et al., 2012; Nakamura et al., 2013). Other studies 
have shown a dose-dependent release of HMGB1 from brain slices cultured after exposure to 
ethanol (Zou & Crews, 2014). 
HMGB1 activates cells through multiple membrane receptors such as TLR2, TLR4 and 
RAGE receptors (Harris et al., 2012). Several TLRs have been suggested to play a role in the 
regulation of inflammatory and neuropathic pain (Christianson et al., 2011; Kim et al., 2013; 
Liu et al., 2012). Moreover TLR2, TLR4 and RAGE are expressed on glial cells and 
inflammatory cells, and TLR4 and RAGE are expressed on sensory neurons (Vincent et al., 
2007; Wadachi & Hargreaves, 2006). Thus pattern recognition receptor those are critical for 
mounting an innate immunoreaction are potentially also vital in pain processing through their 
expression on both neurons and glial cells. In our study, we found that disulfide HMGB1 
induces pain-like behavior in male and female mice, which is mediated mainly via TLR4 
(Figure 21) and to some extent through RAGE, as RAGE KO mice recovered faster than WT 
mice. Under normal conditions, HMGB1 is in its reduced all-thiol state in the intracellular 
compartment (Hoppe et al., 2006). The outcome of our study suggests that all-thiol HMGB1 
is reduced to the disulfide form after release to become a TLR4 ligand that induces 
nociception and activates glial cells (Figure 21). 
Previous reports have shown that blocking the actions of endogenous HMGB1 activity 
attenuates pain-like behavior in experimental models of diabetic, bladder, cancer and nerve-
injury induced pain, indicating that HMGB1 is an important factor in pain pathology in 
multiple conditions (Feldman et al., 2012; Ma et al., 2017; Nakamura et al., 2013; Otoshi et 
al., 2011; P. C. Ren et al., 2012; Shibasaki et al., 2010; Tanaka et al., 2013; Tong et al., 2010; 
Yamasoba et al., 2016).  Our work further expands our insights on the role of HMGB1 as we 
demonstrate that blocking the actions of both peripheral and spinal HMGB1 reverses CAIA-
induced hypersensitivity (Figure 21). However, the sex dimorphism that we observed after 
systemic injection of the HMGB1 neutralizing antibody was unexpected. Even though it has 
been reported that blocking TLR4 in inflammatory and neuropathic-induced pain is 
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associated with sex dimorphism, this effect has been coupled to spinal TLR4. Interestingly, 
we found that blocking the action of spinal HMGB1 reduced hypersensitivity in both male 
and female mice and without signs of sex-dependence (Figure 21). 
 
Figure 21. Proposed HMGB1 mechanism in spinal cord. In CAIA, Persistent action potential from periphery (1) triggers to 
release HMGB1 into the synaptic cleft (2) which could bind to its receptor on glial cells (3), that activates the intracellular 
MAPK pathway resulting in activation of transcriptional factors to produce cytokine and chemokine (4).  Released cytokine 
and chemokine bind to their respective receptor on pro-pre synaptic neuron (5) to activate transduction phenomenon and 
increase hyperexcitability in second order neuron (6). Blocking spinal endogenous HMGB1 with HMGB1 inhibitors (2G7 
and Abox), dampen the hyperexcitability in the second order neuron (7) in male and female mice. i.t. injection of different 
redox form of HMGB1, Intrathecal delivery of disulfide HMGB1 (dsHMGB1) but not all-thiol HMGB1 (atHMGB1) and 
oxidized HMGB1 (oxHMGB1)(1) binds to TLR4 receptor present on the glial cell (microglia and astrocytes) (2), which 
triggers intracellular MAPK pathway (3) with subsequent production of cytokine and chemokine (4). Released cytokine and 
chemokine bind to their receptor on pro-presynaptic neuron (5) and stimulates transduction phenomenon to increased 
hyperexcitability in second order neuron (6). Blocking microglial activity with minocycline (7) resulted into inhibition of 
action potential in male but not in female mice with up regulation of anti-inflammatory and anti-nociceptive proteins (8).  
 
In Paper III, we investigated the effect of disulfide HMGB1 on microglia and studied sex-
dependent mechanisms behind the induction of mechanical hypersensitivity using 
minocycline, a drug that in addition to its antibiotic properties has been associated with 
microglia inhibition. Accumulating animal and human data reveal sex differences in pain, 
both in terms of sensitivity to painful stimuli and effects of pain treatment. The overall aim of 
this study was to determine if there is a sex difference in disulfide HMGB1-induced 
microglial activation and mechanism by which it drives nociception. We found the intrathecal 
delivery of disulfide HMGB1 drives nociceptive signal transmission in a similar fashion in 
male and female mice. Similarly, LPS drives nociception in male and female mice after 
intrathecal delivery (Woller et al., 2016), in contrast other found, intrathecal delivery of LPS 
induces nociception only in male but not in female mice (Sorge et al., 2011). 
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Mounting data support a role of spinal microglia in the development of hypersensitivity in 
different experimental models of pain, which is frequently visualized as an increase in Iba1 
immunoreactivity associated with a change in microglial morphology (larger cell body and 
more ramified processes). We found that disulfide HMGB1-induced morphological signs of 
enhanced microglial reactivity to a similar degree in male and female mice (Figure 21). 
Interestingly, inhibiting microglial activity with minocycline attenuated disulfide HMGB1-
induced hypersensitivity in male but not in the female mice. This finding is in agreement with 
other studies showing sex-dependent effects of inhibiting microglial activity in different 
experimental models of pain (Chen et al., 2017; Sorge et al., 2015; Sorge & Totsch, 2017). 
LCMS analysis of spinal cords from mice treated with minocycline in conjunction with 
intrathecal injection of disulfide HMGB1 revealed a striking difference in regulation of 
protein expression in male and female mice (Figure 21). As minocycline most likely is acting 
on other cells in addition to microglia, (Moller et al., 2016) these data have to be interpreted 
very carefully from a microglia perspective. Anyhow, it is noteworthy that the minocycline 
treatment up-regulates a number of anti-inflammatory and anti-nociceptive proteins, rather 
than blocking protein synthesis, in male but not in female mice. Proteins of particular 
interests are members of the serpin family. Serpins exert their action by binding and 
inhibiting specific serine proteases, SPA3K was identified as a specific inhibitor of tissue 
kallikrein and alterations of the kallikrein-kinin system lead to anti-inflammatory, 
antinociceptive and anti-allergic effect (Bhoola et al., 1992; Clements, 1989; Murray et al., 
1990). In addition, SPA3N has been shown to attenuate neuropathic pain by inhibiting 
leukocyte elastase activity (Vicuna et al., 2015). Haptoglobin, has been reported to induce an 
anti-oxidative, anti-inflammatory and immunoregulatory effect and suggested to suppress 
cellular immune response by activating macrophages and inhibiting TNF production 
(Theilgaard-Monch et al., 2006). Hemopexin has been shown to be anti-inflammatory and to 
downregulate LPS-induced TNF and IL-6 secretion from murine macrophages (Liang et al., 
2009). Lastly, immunomodulatory function of the vitamin D binding protein (VDBP) has 
also been reported (Ghoreishi et al., 2009) together with musculoskeletal pain and migraine 
attacks with vitamin D inadequacy (Abbasi et al., 2012; Nagata et al., 2014). Overall, our 
findings in paper II support, at least to some extent, that there is a sex dimorphism associated 
with microglia inhibition. However, further studies are warranted in order to understand the 
specific mechanism, and the cellular target(s) of minocycline, which differentiates the effects 
observed in male and female mice. 
In Paper IV, we investigated the peripheral role of HMGB1 in CAIA-associated pain in male 
and female mice. Interestingly, while injection of disulfide HMGB1 into the ankle joint 
induced pain-like behavior in male and female mice, systemic inhibition of HMGB1 
attenuates pain-like behavior in male but not in female mice. It is surprising that there is a sex 
dimorphism in blocking peripheral HMGB1 activity and but no difference when injecting 
HMGB1 into the articular joint, especially as systemic delivery of TLR4 antagonists has not 
been associated with differential effects in male and female mice in formalin models (Woller 
et al., 2016). This suggests that HMGB1 may act through receptors other than TLR4 in the 
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periphery, something that we are currently exploring in our laboratory. However, while 
focusing on TLR4, we investigated if there are cell-specific sex-dependent actions of 
disulfide HMGB1 in the ankle joint.  
 
Figure 22. Proposed HMGB1 mechanism at periphery. Intraarticular injection of disulfide HMGB1 (dsHMGB1) but not all-
thiol HMGB1 (atHMGB1) (1) develops pain like behavior (action potential) in male and female mice. In male and female 
mice, disulfide HMGB1 binds to TLR4 on nociceptors (2) which generates action potential (6) and/or it binds to TLR4 on 
myeloid cells (3) initiating MAPK pathway to produce chemokine and cytokines (4), that bind to their receptor on the nerve 
terminal (5) to generate action potential (6). Triggering pain like behavior in male and female mice is different to some 
extends i.e. Nerve terminal activation by cytokine and chemokine from myeloid cells is more prominent in male mice (thick 
arrow) than female mice. 
Our findings do not demonstrate an exclusive cell specificity of HMGB1 in the joint, but, 
though not consistent at all time points, our findings indicate that TLR4 on nociceptors and 
myeloid cells have differential involvement in nociception in male and female mice (Figure 
22). Furthermore, analyses of cytokines and chemokines revealed that male mice responded 
with a more pronounced induction of cytokines and chemokines in response to disulfide 
HMGB1 compared to the female mice. Similar to this, other studies have reported that 
intraperitoneal injection of LPS increases blood levels of IL-6 to a greater extent in males 
(Marriott et al., 2006) and LPS stimulation of macrophages induces a larger cytokine release 
when the cells come from males compared to females (Kahlke et al., 2000; Marriott et al., 
2006). The reason for this difference deserves careful investigation, as it is potentially very 
important for deciphering the role of the innate immune system in inflammation and pain 
processes.  
Concluding remarks 
Altogether, these studies have contributed to advance our understanding of mechanisms 
underlying the pain in arthritis. For the first time, spinal and peripheral HMGB1 was shown 
to be involved in arthritis pain processing. Moreover, we show that the redox state of this 
molecule is critical for its pronociceptive properties, bringing more light on the biological 
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functions of HMGB1 and its action on receptors like TLR4. Finally, I hope that our data will 
be of importance from a translational point of view as it points to HMGB1 as a novel target 
for pain relief, but with the notion that such approach would require advancement of our 
understanding of the sex dimorphism associated with TLR4. Our work indeed brings 
attention to the need of exploring pain mechanisms in both males and females
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